HowardJHochsterMD

Internal Medicine • Bronx, NY

Physician

Join to view full profile

Are you Dr. Hochster?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
2233 Esplanade Ave
Bronx, NY 10469
Phone+1 718-918-1100

Fax+1 718-918-1106

Summary

Dr. Howard Hochster, MD is an internist in Bronx, New York. He is currently licensed to practice medicine in New York. He is affiliated with Montefiore Medical Center and Burke Rehabilitation Hospital.

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1998 - 2001
Albert Einstein College of MedicineClass of 1998

Certifications & Licensure

NY State Medical License 2000 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013

Clinical Trials

Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer Start of enrollment: 1993 Sep 01
Completed
Phase 1
Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors Start of enrollment: 1994 Sep 01
Completed
Phase 1
Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer Start of enrollment: 1995 Dec 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Cancer Start of enrollment: 1998 Jan 01
Completed
Phase 1
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer Start of enrollment: 1997 Jul 01
Completed
Phase 1, Phase 2
Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer Start of enrollment: 1999 Feb 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1999 Jan 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors Start of enrollment: 1999 Oct 01
Completed
Phase 1
Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer Start of enrollment: 2000 Oct 09
Completed
Phase 2
Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1999 Aug 01
Completed
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer Start of enrollment: 1999 Aug 01
Completed
Phase 2
R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Aug 01
Completed
Phase 1
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2000 Aug 01
Completed
Phase 1
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer Start of enrollment: 2003 Jul 01
Terminated
Phase 1
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Start of enrollment: 2019 Dec 02
Active, not recruiting
Phase 2
Join now to see all

Press Mentions

Role of Immunotherapy Agents Grows in Metastatic Colorectal CancerJanuary 5th, 2020